` SNT (Syntara Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

SNT
vs
S&P/ASX 300

Over the past 12 months, SNT has significantly outperformed S&P/ASX 300, delivering a return of 96% compared to the S&P/ASX 300's 9% growth.

Stocks Performance
SNT vs S&P/ASX 300

Loading
SNT
S&P/ASX 300
Add Stock
www.alphaspread.com

Performance Gap
SNT vs S&P/ASX 300

Loading
SNT
S&P/ASX 300
Difference
www.alphaspread.com

Performance By Year
SNT vs S&P/ASX 300

Loading
SNT
S&P/ASX 300
Add Stock

Competitors Performance
Syntara Ltd vs Peers

S&P/ASX 300
SNT
LLY
JNJ
NOVO B
ROG
Add Stock

Syntara Ltd
Glance View

Market Cap
74.2m AUD
Industry
Pharmaceuticals

Syntara Ltd is a AU-based company operating in Pharmaceuticals industry. The company is headquartered in Frenchs Forest, New South Wales. The company went IPO on 2003-11-10. Syntara Limited, formerly Pharmaxis Ltd, is an Australia-based clinical-stage drug development company with a focus on blood-related cancers. The Company’s highly productive drug discovery engine is driven by its expertise in amine oxidase inhibitors. Its lead candidate, PXS-5505, is used for the bone marrow cancer myelofibrosis, which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. The firm is also advancing both oral and topical pan-LOX inhibitors in scar prevention and scar modification programs. Its PXS-4728 is a SSAO/MAOB inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson’s by reducing neuroinflammation. The Company’s other drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis, and cardiac fibrosis. The company has developed two respiratory products: Bronchitol, for cystic fibrosis, and Aridol, a lung function test.

SNT Intrinsic Value
0.012 AUD
Overvaluation 74%
Intrinsic Value
Price
Back to Top